Expression-Based Subtypes Define Pathologic Response to Neoadjuvant Immune-Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer

Study

Study ID	Alternative Stable ID	Type
EGAS00001005549		Other

Study Description

Checkpoint immunotherapy (CPI) has increased survival for some patients with advanced stage bladder cancer (BCa). However, most patients do not respond. Here, we characterized the tumor and immune microenvironment in pre- and post-treatment tumors from the PURE01 neoadjuvant pembrolizumab immunotherapy trial, using a consolidative approach that combined transcriptional and genetic profiling with digital spatial profiling.

Study Datasets 6 datasets.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001007998	ATACseq FASTq files from RT4 cells treated with KDM5i C70 ATACseq FASTq files from RT4 cells treated with KDM5i C70	Illumina HiSeq 4000	4
EGAD00001007999	RNAseq FASTq files from RT4 cells treated with FGFRi Erdafitinib RNAseq FASTq files from RT4 cells treated with FGFRi Erdafitinib	Illumina NovaSeq 6000	6
EGAD00001008000	RNAseq FASTq files from RT4 cells treated with KDM5i C70 RNAseq FASTq files from RT4 cells treated with KDM5i C70	Illumina NovaSeq 6000	6
EGAD00001008001	single-cell RNAseq FASTq files for three muscle-invasive bladder tumors single-cell RNAseq FASTq files for three muscle-invasive bladder tumors	Illumina HiSeq 2500	12
EGAD00001008002	RNAseq FASTq files from 31 post-treatment tumors from PURE01 RNAseq FASTq files from 31 post-treatment tumors from PURE01	Illumina HiSeq 2500	31
EGAD00001008003	RNAseq FASTq files from 82 pre-treatment tumors from PURE01 RNAseq FASTq files from 82 pre-treatment tumors from PURE01	Illumina HiSeq 4000	82

Who archives the data?

Publications

Citations

Retrieving...